Three-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Final results of the ABSORB EXTEND trial
Catheterization and Cardiovascular Interventions Oct 10, 2018
Costa JR, et al. - Researchers assessed the 3-year performance of the Absorb bioresorbable vascular scaffolds for the treatment of low/moderate complexity patients enrolled in the ABSORB EXTEND trial— a prospective, single-arm, open-label clinical study. Participants included 812 individuals enrolled at 56 sites, of whom 26.5% had diabetes. They found that, at 3-year follow-up, the use of ABSORB in low/moderate complex PCI was linked to low and acceptable rates of major adverse clinical events, irrespective of the infrequent use of the commended contemporary scaffold deployment technique. The rate of scaffold thrombosis was higher than reported with current generation of metallic DES.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries